On 26 February 2019, orphan designation (EU/3/19/2142) was granted by the European Commission to 3R Pharma Consulting GmbH, Germany, for losartan for the treatment of epidermolysis bullosa.
The sponsorship was transferred to Crowd Pharma Losartan GmbH & Co. KG, Germany, in March 2022.
Treatment of epidermolysis bullosa
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: